Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pruritus associated with systemic sclerosis: a systematic review of treatment-based clinical trials.

Rheumatology international·2026
Same author

Stress exposure prior to diagnosis and clinical characteristics in systemic lupus erythematosus: a cross-sectional study.

Rheumatology international·2026
Same author

Systemic sclerosis and primary biliary cholangitis: a systematic review of case-control studies comparing isolated and overlapping disease phenotypes.

Journal of scleroderma and related disorders·2026
Same author

Transcatheter Aortic Valve Replacement in Systemic Sclerosis: A Case Series and Review of Short- and Long-Term Outcomes.

Mediterranean journal of rheumatology·2026
Same author

Systemic Sclerosis-Associated Interstitial Lung Disease: Improved Understanding and Advances in Management.

British journal of hospital medicine (London, England : 2005)·2025
Same author

Understanding spiritual well-being in patients with systemic sclerosis and its effect on the illness: a scoping review.

Clinical rheumatology·2025

Related Experiment Video

Updated: Jun 13, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Scleroderma lung disease: treatment with cyclophosphamide.

Steffan Schulz1, Lindsay Bischoff, David Michel

  • 1Thomas Jefferson University, Division of Rheumatology, 613 Curtis Building, 1015 Walnut Street, Philadelphia, PA 19107, USA. setffan.shultz@maill.tju.edu

Expert Review of Clinical Immunology
|May 19, 2010
PubMed
Summary

Oral cyclophosphamide offers modest benefits for scleroderma lung disease, according to a placebo-controlled trial. However, high dropout rates and side effects limit its clinical applicability.

More Related Videos

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin
06:52

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin

Published on: April 30, 2019

Related Experiment Videos

Last Updated: Jun 13, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin
06:52

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin

Published on: April 30, 2019

Area of Science:

  • Pulmonary Medicine
  • Rheumatology
  • Clinical Pharmacology

Background:

  • Systemic sclerosis frequently causes interstitial lung disease, a major cause of mortality.
  • Effective treatments for scleroderma lung disease are limited, creating a significant unmet clinical need.
  • This study evaluated oral cyclophosphamide for treating scleroderma lung disease.

Discussion:

  • The study employed a prospective, double-blinded, placebo-controlled design.
  • Outcomes included forced vital capacity and patient-reported disability scores.
  • Results indicated a statistically significant but modest benefit of cyclophosphamide.

Key Insights:

  • Oral cyclophosphamide demonstrated a measurable, albeit small, positive effect on scleroderma lung disease outcomes.
  • The study highlights the challenges in treating this condition effectively.
  • Limitations included a high participant dropout rate and the drug's side-effect profile.

Outlook:

  • Further research is needed to optimize cyclophosphamide use or identify alternative therapies.
  • The choice of forced vital capacity as a primary outcome warrants consideration in future studies.
  • Clinical integration of these findings is tempered by the observed limitations.